Impact of Thoracic Scans on Patients with Blood Cancers
Clinical Impact of Thoracic Scanographic Characteristics of Hematologic Malignancy Patients with Mediastinal Mass Syndrome Admitted to the Intensive Care Unit
This study looks at how chest scans can help doctors better manage patients with blood cancers who have breathing problems caused by a mass in their chest.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 125 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | Prednisone |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT05694806 on ClinicalTrials.gov |
What this trial studies
This observational study examines the characteristics of thoracic scans in patients diagnosed with hematologic malignancies who are experiencing mediastinal mass syndrome (MMS). The research focuses on the diagnostic and therapeutic challenges posed by MMS, which can lead to various respiratory and vascular complications. By analyzing thoracic computed tomography (CT) scans, the study aims to improve the management of patients admitted to intensive care for symptom relief and treatment planning. The study spans an eight-year period, collecting data on patients who meet specific inclusion criteria related to their condition and treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a diagnosis of hematologic malignancy who are symptomatic and have been admitted to intensive care due to mediastinal mass syndrome.
Not a fit: Patients without a diagnosis of hematologic malignancy or those with solid tumors will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the diagnostic accuracy and treatment strategies for patients suffering from mediastinal mass syndrome associated with hematologic malignancies.
How similar studies have performed: While there is limited information on similar studies, the approach of analyzing thoracic scans in this context is relatively novel and may provide new insights into managing mediastinal mass syndrome.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hematologic malignancy at diagnosis or relapse * Symptomatic mediastinal mass syndrome * Admission to the ICU, Continuous Medical Surveillance (CMS) or Intensive Care (IC) for symptomatology related to MMS * Chest CT (after maximum 48 hours of corticosteroid therapy (1mg/kg/ Prednisone equivalent), maximum 15 days before and 5 days after admission to ICU) * Maximum administration of corticosteroid therapy 48 hours before admission to the ICU (maximum 1mg/kg/ Prednisone equivalent) * No prior pleural or pericardial drainage * Study period: 01/01/2014 - 31/12/2021 (8 years) Exclusion Criteria: * No diagnosis of hematologic malignancy * Diagnosis of solid benign or malignant tumor * No mediastinal mass syndrome * No admission to ICU/CMS * No chest CT scan meeting inclusion criteria * Administration of corticosteroids for more than 48 hours prior to admission to the ICU and/or prior to chest CT * Lack of social security affiliation.
Where this trial is running
Toulouse
- Muriel Picard — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Muriel Picard, MD — University Hospital, Toulouse
- Study coordinator: Muriel Picard, MD
- Email: picard.m@chu-toulouse.fr
- Phone: 0561756105
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.